Aims-To determine whether the CHA 2 DS 2 -VASc score can predict adverse outcomes such as death, ischemic stroke, and major hemorrhage, in patients with systolic heart failure in sinus rhythm.
Background
Patients with heart failure with reduced ejection fraction (HFrEF) are at increased risk for adverse outcomes, including death and stroke. (1, 2) For patients with HFrEF in sinus rhythm, there has been recent interest in assessing whether the risk of these adverse outcomes can be accurately predicted by existing risk scores that incorporate established risk factors. (3) (4) (5) In particular, although the CHA 2 DS 2 -VASc risk score (incorporating risk factors including congestive heart failure, hypertension, age ≥75 years [2 points], age 65-75 years, diabetes, stroke/transient ischemic attack/thromboembolism [2 points], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], and female sex) was developed for patients with atrial fibrillation,(6) Melgaard and colleagues recently described its use for predicting the risk of death and stroke in HFrEF patients in sinus rhythm. (3) We therefore undertook this analysis of patients enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial (WARCEF), (7) to evaluate whether the CHA 2 DS 2 -VASc risk score can predict death, ischemic stroke, and major hemorrhage in patients with HFrEF in sinus rhythm who received warfarin or aspirin.
Methods
The protocol for the randomized, double blinded WARCEF trial (http:// www.ClinicalTrials.gov No. NCT00041938) has been described previously. (7, 8) Briefly, patients with left ventricular ejection fraction (LVEF) ≤35% and who were in SR were randomized to receive warfarin or aspirin. Additional eligibility criteria included age ≥18 years old, having no contraindications to warfarin, having a modified Rankin score of 4 or less, and on evidence-based heart failure medications (beta-blocker, angiotensin-convertingenzyme inhibitor or angiotensin-receptor blocker, or hydralazine and nitrates). Patients were excluded if they had a clear indication for warfarin or aspirin, or if they had a condition that conferred a high risk of cardiac embolism. A total of 2,305 participants were recruited from 168 centers in 11 countries from October 2002 to January 2010. The investigation conforms with the principles outlined in the Declaration of Helsinki.(9) All subjects provided informed consent.
For the WARCEF trial, ischemic stroke was defined as a clinically relevant new lesion detected on computed tomography or magnetic resonance imaging or, in the absence of a new lesion, clinical findings that were consistent with the occurrence of clinical stroke and that lasted for longer than 24 hours. Major bleeding was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. A blinded independent end-point adjudication committee adjudicated all stroke and major bleeding events.
For each participant, the CHA 2 DS 2 -VASc risk score was calculated based on the approach described by Lip and colleagues.(6) For this analysis, 81 participants were excluded because incomplete data precluded the calculation of the CHA 2 DS 2 -VASc score. Because stroke and bleeding risk are expected to differ for patients receiving warfarin and aspirin, we performed all analyses separately for the warfarin and aspirin arms of the WARCEF trial on an intentto-treat (ITT) basis. Baseline characteristics of the study participants were compared by treatment group using two-sample t-test for continuous variables and Chi-squared test categorical variables. For each CHA 2 DS 2 -VASc score, we calculated incidence rate per 100 patient-years for the composite outcome of death and ischemic stroke, as well as for the individual outcomes of death, ischemic stroke, and major bleeding. Exact Poisson 95% confidence intervals of the incidence rates were provided. To determine the association between CHA 2 DS 2 -VASc score and each outcome above, as well as to investigate whether the CHA 2 DS 2 -VASc score influenced the treatment effect of warfarin versus aspirin, we constructed Cox proportional hazard models that incorporated treatment assignment, the CHA 2 DS 2 -VASc score, and their interaction term. Model discrimination was assessed using Harell's c-index. Model calibration was assessed using the survival-adapted HosmerLemeshow χ 2 goodness of fit test. (10) The test statistic measures the difference between the predicted and the observed probabilities of risk. A small p-value suggests that the model is not well calibrated. P-values of <0.05 were considered statistically significant for all testing. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
Results
For this analysis, a total of 2,204 participants were included, of whom 1,101 were enrolled in the warfarin arm and 1,123 were enrolled in the aspirin arm. The mean (SD) age of participants were 60.8 (11.3) years old, and 435 (19.6%) were female. Baseline characteristics of WARCEF participants by treatment arm are described in Table 1 .
Because all WARCEF participants had a diagnosis of heart failure, the minimum CHA 2 DS 2 -VASc score was 1; the maximum was 9. The composite outcome of death and ischemic stroke occurred in 588 (27%) of the 2,204 participants; the risk significantly increased with each 1-point increase in CHA 2 DS 2 -VASc score (Figure) for participants enrolled in both warfarin (hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.13-1.30, p<0.001) and aspirin arms (HR 1.20, 95% CI 1.11-1.29, p<0.001) . Similar trends were observed for the individual outcomes of ischemic stroke (Table 2) , death alone and major hemorrhage (Table  3) . For ischemic stroke, the incidence rate per 100 patient-years was largely above 1% for CHA 2 DS 2 -VASc scores of 5 and above for patients receiving warfarin, and for CHA 2 DS 2 -VASc scores of 2 and above for patients receiving aspirin.
The treatment effect of warfarin versus aspirin did not significantly differ according to the CHA 2 DS 2 -VASc score for all outcomes examined. Model discrimination was modest for the composite outcome of death and ischemic stroke (c-index 0.58, 95% CI 0.56-0.60) and the individual outcome of death (c-index 0.57, 95% CI 0.55-0.60), but was higher for ischemic stroke (c-index 0.64, 95% CI 0.57-0.70) and for major hemorrhage (c-index 0.68, 95% CI 0.62-0.73) (Tables 2 and 3 ). The survival-adapted Hosmer-Lemeshow goodness-of-fit test pvalues were larger than 0.05 for all outcomes, suggesting that none of the models had a significant lack of fit.
Discussion
In this retrospective analysis of the WARCEF trial, we found that in patients with heart failure in sinus rhythm, the CHA 2 DS 2 -VASc score was moderately predictive of adverse outcomes, including death or ischemic stroke, and the individual outcomes of death, ischemic stroke, and major hemorrhage. Increased CHA 2 DS 2 -VASc risk score was consistently associated with increased stroke risk for both the aspirin and warfarin arms of the WARCEF cohort. There was no significant interaction between treatment assignment and the CHA 2 DS 2 -VASc score for these outcomes.
Our results are largely consistent with those reported by Melgaard and colleagues, who found that the CHA 2 DS 2 -VASc score predicted death, ischemic stroke, and thromboembolism, in a nationwide cohort of 33,592 heart failure patients with reduced or preserved ejection fraction without concurrent atrial fibrillation. (3) In that study, the cstatistics for the CHA 2 DS 2 -VASc ranged from 0.63 to 0.69 for the individual outcomes. These values are slightly higher than those in our analysis. However, at each level of the CHA 2 DS 2 -VASc score, the absolute risk for ischemic strokes was higher in the Danish cohort, ranging from 1.5% per year for a score of 1 to 7% for a score of 6, where as across the same range of CHA 2 DS 2 -VASc scores in the WARCEF cohort the stroke risk was 0.3% to 1.1% in the aspirin arm and 0.4% to 1.1% in the warfarin arm. Potential reasons for this include the protective effects of aspirin and warfarin, inclusion of younger patients in WARCEF, and statistical imprecision due to the sample size. Regardless of the reason, these differences suggest additional analyses of independent cohorts are needed to better calibrate how the CHA 2 DS 2 -VASc score can predict stroke risk in heart failure patients in sinus rhythm, especially as the threshold for benefit from initiating anticoagulation is commonly thought to be a stroke risk of between 1-2%. (11, 12) In addition to the CHA 2 DS 2 -VASc score, other approaches to risk stratification for heart failure patients in sinus rhythm have been examined recently. Abdul-Rahim and colleagues have found that in in patients with heart failure with reduced ejection fraction who are in sinus rhythm, risk scores that included clinical risk factors (age, New York Heart Association class, diabetes treated with insulin, body mass index, previous stroke) and Nterminal pro B-type natriuretic peptide accurately predicted strokes.(4) Similarly, we have previously demonstrated that major bleeding in WARCEF participants could be predicted by existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score and the Outpatient Bleeding Risk Index (OBRI). (5) Taken together, these findings all suggest that risk prediction in heart failure patients in sinus rhythm can be further refined. Although current guidelines do not recommend routine anticoagulation in this patient population, (13, 14) ongoing studies, such as the COMMANDER-HF randomized, controlled trial, are assessing the potential benefit of newer oral anticoagulants such as rivaroxaban. (15) Given the superior safety profile of these agents compared with warfarin, improved risk stratification of heart failure patients in sinus rhythm, especially with regards to stroke and bleeding risk, (16, 17) will greatly aid the identification of patients who may benefit from such therapy. (11) The limitations of our analysis include its retrospective design and the modest number of stroke events. As mentioned previously, since WARCEF was a randomized, controlled trial, it is possible that healthier patients were selected, which could lead to underestimation of stroke risk and affect the generalizability of our findings. Similarly, since all patients in WARCEF received either warfarin or aspirin, the true stroke risk of heart failure patients in sinus rhythm who are not on anticoagulant therapy may be higher than described here. We did not construct a model including hemodynamic or laboratory parameters using WARCEF participants, and it is possible such a model may be superior to the CHA2DS2-VASc risk score. However, any such model would also need to be validated externally, while the CHA2DS2-VASc risk score is easy to calculate and already widely accepted, making it more likely to be clinically useful should future studies continue to confirm our findings. Finally, we did not formally monitor for the occurrence of asymptomatic atrial fibrillation during the WARCEF study, although a small number of participants (~10%) did develop clinical atrial fibrillation during the follow-up period. (18) Although this may have contributed to the relationship between the CHA2DS2-VASc score and clinical outcomes observed in our analysis, this does not change our finding that the CHA2DS2-VASc score represents a potentially useful tool for risk stratification in this patient population.
Despite these limitations, our findings are timely additions to the literature on understanding stroke risk in heart failure patients in sinus rhythm. Our analysis confirms that the CHA 2 DS 2 -VASc score can predict stroke risk in this population, and can potentially inform future studies on new therapeutic approaches for stroke prevention for heart failure patients in sinus rhythm. Adverse outcomes by CHA 2 DS 2 -VASc score. Incidence rate of ischemic stroke (top panel), and death or ischemic stroke (bottom panel), by categories of CHA 2 DS 2 -VASc score. Because only 1 patient had a CHA 2 DS 2 -VASc score of 9, data are not shown for that category. Baseline characteristics of the study participants, according to treatment group (warfarin versus aspirin). For continuous variables, mean ± SD were reported, and p-values were calculated using two-sample t-test. For categorical variables, number /total number (%) were reported, and p-values were calculated using Chisquared test.
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